.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,846,563

« Back to Dashboard

Details for Patent: 5,846,563

Title: Sustained release heterodisperse hydrogel systems for insoluble drugs
Abstract:A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.
Inventor(s): Baichwal; Anand R. (Wappingers Falls, NY)
Assignee: Edward Mendell Co., Inc. (Patterson, NY)
Filing Date:Apr 18, 1997
Application Number:08/843,573
Claims:1. A sustained release composition, comprising:

an effective amount of a medicament having a solubility of less than about 10 g/l to render a therapeutic effect; admixed together with sustained release agglomerated particles comprising a gelling agent, an inert pharmaceutical diluent, the ratio of said inert diluent to said gelling agent being from about 1:8 to about 8:1, and a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, shellac, waxes, zein and mixtures of any of the foregoing, said hydrophobic material being included in an amount effective to slow the hydration of said gelling agent when said dosage form is exposed to an environmental fluid.

2. The sustained release composition of claim 1, wherein said gelling agent comprises xanthan gum and locust bean gum in a ratio from about 1:3 to about 3:1.

3. The sustained release composition of claim 1, wherein said hydrophobic polymer is included in an amount from about 1% to about 20% by weight of said sustained release agglomerated particles.

4. The sustained release composition of claim 1, wherein said hydrophobic polymer is included in an amount from about 1% to about 10% by weight of said composition.

5. The sustained release composition of claim 1, wherein said medicament is nifedipine.

6. The sustained release composition of claim 1, wherein the amount of nifedipine is 20 mg, 30 mg, 60 mg or 90 mg.

7. The sustained release composition of claim 1 which is a tablet, at least part of a surface of said tablet being coated with a hydrophobic polymer to a weight gain from about 1 to about 20 percent, by weight.

8. The sustained release composition of claim 7, wherein said coating comprises a hydrophobic material selected from the group consisting of an alkylcellulose, a copolymer of acrylic and methacrylic acid esters, waxes, shellac, zein, hydrogenated vegetable oils, and a mixture of any of the foregoing.

9. The sustained release composition of claim 1, wherein the mixture of said medicament and said sustained release agglomerated particles are granulated with a second hydrophobic material selected from the group consisting of an alkylcellulose, a copolymer of acrylic and methacrylic acid esters, waxes, shellac, zein, hydrogenated vegetable oils, and a mixture of any of the foregoing.

10. The sustained release composition of claim 1, wherein said mixture is compressed into a tablet.

11. The sustained release composition of claim 9, wherein said mixture is compressed into a tablet.

12. A sustained release oral solid dosage form for absorption of a therapeutically active medicament in the gastrointestinal tract, comprising:

an effective amount of a medicament having a solubility of less than about 10 g/l to render a therapeutic effect; and

a sustained release excipient comprising a gelling agent, an inert pharmaceutical diluent selected from the group consisting of monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, the ratio of said inert diluent to said gelling agent being from about 1:8 to about 8:1, said gelling agent and said inert pharmaceutical diluent being granulated with a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, shellac, waxes, zein and mixtures of any of the foregoing, prior to the incorporation of said medicament, said hydrophobic polymer being included in an amount effective to slow the hydration of said gelling agent when said dosage form is exposed to an environmental fluid.

13. A sustained release oral solid dosage form for absorption of a therapeutically active medicament in the gastrointestinal tract, comprising:

an effective amount of a medicament having a solubility of less than about 10 g/l to render a therapeutic effect; and

a sustained release excipient comprising xanthan gum, locust bean gum, an inert pharmaceutical diluent selected from the group consisting of monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, the ratio of said inert diluent to the total amount of said xanthan gum and said locust bean gum being from about 1:8 to about 8:1; and a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, shellac, waxes, zein and mixtures of any of the foregoing, said hydrophobic material being included in an amount effective to slow the hydration of said gelling agent when said dosage form is exposed to an environmental fluid.

14. A sustained release composition, comprising agglomerated particles comprising

an effective amount of a medicament having a solubility of less than about 10 g/l to render a therapeutic effect;

a gelling agent;

an inert pharmaceutical diluent, the ratio of said inert diluent to said gelling agent being from about 1:8 to about 8:1; and

a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, shellac, waxes, zein and mixtures of any of the foregoing, said hydrophobic polymer being included in an amount from about 1% to about 10% by weight of said composition.

15. The sustained release composition of claim 14, wherein said gelling agent comprises xanthan gum and locust bean gum in a ratio from about 1:3 to about 3:1.

16. The sustained release composition of claim 14, wherein said medicament comprises a dihydropyridine.

17. The sustained release composition of claim 14, wherein said agglomerated particles are granulated with a second hydrophobic material selected from the group consisting of an alkylcellulose, a copolymer of acrylic and methacrylic acid esters, waxes, shellac, zein, hydrogenated vegetable oils, and a mixture of any of the foregoing.

18. The sustained release composition of claim 17, wherein said mixture is compressed into a tablet.

19. The sustained release composition of claim 14, wherein said mixture is compressed into a tablet.

20. A sustained release oral solid dosage form for providing an effective dose of nifedipine over a 24 hour period, comprising

from about 20 mg to about 90 mg of nifedipine;

xanthan gum and locust bean gum in a ratio from about 1:3 to about 3:1;

an inert pharmaceutical diluent, the ratio of said inert diluent to the total amount of said xanthan gum and said locust bean gum being from about 1:8 to about 8:1; and

a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, shellac, waxes, zein and mixtures of any of the foregoing, said hydrophobic polymer being included in an amount from about 1% to about 10% by weight of said dosage form.

21. The dosage form of claim 20, which is in the form of a tablet.

22. The dosage form of claim 21, wherein said tablet is coated with a hydrophobic coating to a weight gain from about 1 to about 20 percent of the total weight of said tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc